Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole

Autores
Fernández, Marisa Liliana; Marson, María Elena; Ramírez, Juan Carlos; Mastrantonio Garrido, Guido Enrique; Schijman, Alejandro Gabriel; Altcheh, Jaime; Riarte, Adelina Rosa; García Bournissen, Facundo
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/ day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.
Facultad de Ciencias Exactas
Materia
Biología
Benznidazole
Chagas disease
Pharmacology
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/86271
Acceder
id SEDICI_92f41a8377adb5bf11d7535da29f50d5
oai_identifier_str oai:sedici.unlp.edu.ar:10915/86271
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazoleFernández, Marisa LilianaMarson, María ElenaRamírez, Juan CarlosMastrantonio Garrido, Guido EnriqueSchijman, Alejandro GabrielAltcheh, JaimeRiarte, Adelina RosaGarcía Bournissen, FacundoBiologíaBenznidazoleChagas diseasePharmacologyPharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/ day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.Facultad de Ciencias Exactas2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf218-221http://sedici.unlp.edu.ar/handle/10915/86271enginfo:eu-repo/semantics/altIdentifier/issn/0074-0276info:eu-repo/semantics/altIdentifier/doi/10.1590/0074-02760150401info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:16:49Zoai:sedici.unlp.edu.ar:10915/86271Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:16:49.473SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
title Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
spellingShingle Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
Fernández, Marisa Liliana
Biología
Benznidazole
Chagas disease
Pharmacology
title_short Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
title_full Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
title_fullStr Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
title_full_unstemmed Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
title_sort Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
dc.creator.none.fl_str_mv Fernández, Marisa Liliana
Marson, María Elena
Ramírez, Juan Carlos
Mastrantonio Garrido, Guido Enrique
Schijman, Alejandro Gabriel
Altcheh, Jaime
Riarte, Adelina Rosa
García Bournissen, Facundo
author Fernández, Marisa Liliana
author_facet Fernández, Marisa Liliana
Marson, María Elena
Ramírez, Juan Carlos
Mastrantonio Garrido, Guido Enrique
Schijman, Alejandro Gabriel
Altcheh, Jaime
Riarte, Adelina Rosa
García Bournissen, Facundo
author_role author
author2 Marson, María Elena
Ramírez, Juan Carlos
Mastrantonio Garrido, Guido Enrique
Schijman, Alejandro Gabriel
Altcheh, Jaime
Riarte, Adelina Rosa
García Bournissen, Facundo
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Biología
Benznidazole
Chagas disease
Pharmacology
topic Biología
Benznidazole
Chagas disease
Pharmacology
dc.description.none.fl_txt_mv Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/ day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.
Facultad de Ciencias Exactas
description Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/ day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/86271
url http://sedici.unlp.edu.ar/handle/10915/86271
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/0074-0276
info:eu-repo/semantics/altIdentifier/doi/10.1590/0074-02760150401
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
218-221
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1844616040858779648
score 13.070432

Publicaciones similares